Clinical Microbiology and Infection最新文献

{"title":"Should multiplex PCR testing be integrated into antimicrobial stewardship programs for paediatric community-acquired pneumonia in the emergency department?","authors":"Paul Loubet, Slim Fourati, Donia Bouzid","doi":"10.1016/j.cmi.2024.08.028","DOIUrl":"10.1016/j.cmi.2024.08.028","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"5-7"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which trial do we need? Combination therapy with daptomycin plus ceftaroline versus standard-of-care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteraemia.","authors":"Myeongji Kim, Nischal Ranganath, Supavit Chesdachai, Ryan W Stevens, Muhammad Rizwan Sohail, Omar M Abu Saleh","doi":"10.1016/j.cmi.2024.08.011","DOIUrl":"10.1016/j.cmi.2024.08.011","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"18-21"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steroids for viral meningitis: a foe or a friend?","authors":"Rodrigo Hasbun","doi":"10.1016/j.cmi.2024.09.030","DOIUrl":"10.1016/j.cmi.2024.09.030","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"8-9"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nirmatrelvir/ritonavir treatment and risk for post-acute sequelae of COVID-19 in older Singaporeans: author's response.","authors":"Liang En Wee, Jue Tao Lim, An Ting Tay, Calvin J Chiew, Barnaby Edward Young, Betty Wong, Ruth Lim, Ching Li Lee, Joyce Tan, Shawn Vasoo, David Chien Lye, Kelvin Bryan Tan","doi":"10.1016/j.cmi.2024.10.002","DOIUrl":"10.1016/j.cmi.2024.10.002","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"139-140"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates.","authors":"Christophe Le Terrier, Patrice Nordmann, Adam Delaval, Laurent Poirel","doi":"10.1016/j.cmi.2024.10.012","DOIUrl":"10.1016/j.cmi.2024.10.012","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"122-124"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: 'ESR and CRP: it's time to stop the zombie tests' by Spellberg et al.","authors":"Angela Huttner, Pranita D Tamma, Dafna Yahav","doi":"10.1016/j.cmi.2024.09.016","DOIUrl":"10.1016/j.cmi.2024.09.016","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"134-135"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious complications in the paediatric immunocompromised host: a narrative review.","authors":"Thomas Lehrnbecher, Andreas H Groll","doi":"10.1016/j.cmi.2024.06.002","DOIUrl":"10.1016/j.cmi.2024.06.002","url":null,"abstract":"<p><strong>Background: </strong>Infections are a major cause of morbidity in children with primary or secondary immunodeficiency, and have a negative impact on overall outcome.</p><p><strong>Objectives: </strong>This narrative review presents select paediatric-specific aspects regarding the clinical impact, diagnosis, management, and follow-up of infectious complications in patients with primary and secondary immunodeficiencies.</p><p><strong>Sources: </strong>PubMed until January 2024 and searched references in identified articles including the search terms: infection, immunodeficiency or cancer, diagnostics, antimicrobial agents, bacteria or fungus or virus, and follow-up.</p><p><strong>Content: </strong>Major advances have been made in the early detection and management of patients with primary immunodeficiency, and multiple analyses report in children with cancer on risk groups and periods of risk for infectious complications. Although many diagnostic tools are comparable between children and adults, specific considerations have to be applied, such as minimizing the use of radiation. Antimicrobial drug development remains a major challenge in the paediatric setting, which includes the establishment of appropriate dosing and paediatric approval. Last, long-term follow-up and the impact of late effects are extremely important to be considered in the management of immunocompromised paediatric patients.</p><p><strong>Implications: </strong>Although infectious disease supportive care of immunocompromised children and adolescents has considerably improved over the last three decades, close international collaboration is needed to target the specific challenges in this special population.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"37-42"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of helminthiases in travellers and migrants with eosinophilia: a cohort study.","authors":"Maëli van Waasdijk, Suzanne D van der Werff, Daniel Sjöholm, Katja Wyss, Hilmir Asgeirsson, Pontus Naucler, Anna Färnert, Ana Requena-Méndez","doi":"10.1016/j.cmi.2024.10.009","DOIUrl":"10.1016/j.cmi.2024.10.009","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to determine predictors for helminthiasis among travellers and migrants with eosinophilia for which a visit to tropical regions or endemic regions for common helminthiasis had been registered.</p><p><strong>Methods: </strong>A retrospective cohort study was performed using electronic health records of 23 905 patients with eosinophilia (January 2011-August 2021) at Karolinska University Hospital, Stockholm, including patients tested for helminthiasis with a registered stay in a helminth endemic region. Outcomes were diagnosis of any helminthiasis and diagnosis of schistosomiasis and strongyloidiasis. Multivariable logistic regression was used to assess associations between potential predictors and helminthiases with a backwards stepwise elimination approach until a predictive model was reached in which each variable had a p value < 0.15.</p><p><strong>Results: </strong>Of 1112 eligible patients with eosinophilia and documented stay in endemic regions, 219 (19.7%) had been diagnosed with helminthiasis, most frequently schistosomiasis (n = 95, 43.4%) and strongyloidiasis (n = 64, 29.2%). A stay in Sub-Saharan Africa (SSA) (OR, 8.2; 95% CI, 2.44-27.56), malaise and fatigue (OR 2.65; 95% CI, 0.77-9.09), and high-grade eosinophilia >1500 cells/μL (OR 2.26; 95% CI, 1.54-3.32) were the most important predictors for any helminthiasis (area under the curve [AUC], 0.77; 0.74-0.80). An SSA origin (AUC, 2.97; 1.11-7.95), malaise and fatigue (AUC, 5.48; 1.13-26.63), and high-grade eosinophilia (AUC, 1.53; 0.86-2.71) were predictors for schistosomiasis (AUC, 0.74; 0.70-0.77); whereas SSA origin (AUC, 5.68 (3.04-10.59)), itching symptoms (AUC, 5.05; 1.32-19.36), and high-grade eosinophilia (AUC, 2.42; 1.33-4.41) were predictors for strongyloidiasis (AUC, 0.73; 0.69-0.76).</p><p><strong>Discussion: </strong>A stay in an endemic region, specifically SSA, having high-grade eosinophilia, and malaise and fatigue were the most important predictors for helminthiasis. Itching was an additional predictor for strongyloidiasis.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"113-120"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans.","authors":"Liang En Wee, Jue Tao Lim, An Ting Tay, Calvin J Chiew, Barnaby Edward Young, Betty Wong, Ruth Lim, Ching Li Lee, Joyce Tan, Shawn Vasoo, David Chien Lye, Kelvin Bryan Tan","doi":"10.1016/j.cmi.2024.08.019","DOIUrl":"10.1016/j.cmi.2024.08.019","url":null,"abstract":"<p><strong>Objectives: </strong>Significant heterogeneity has been reported in cohort studies evaluating the impact of early oral antiviral treatment on preventing postacute sequelae after COVID-19. We evaluated the impact of early nirmatrelvir/ritonavir on risk of postacute cardiovascular, neurological, respiratory, and autoimmune diagnoses, as well as postacute symptoms amongst older Singaporeans.</p><p><strong>Methods: </strong>National COVID-19 registries and healthcare claims databases were used to construct a retrospective population-based cohort enrolling all Singaporeans aged ≥60 years diagnosed with SARS-CoV-2 infection in primary care during Omicron transmission (18 March 2022-4 August 2023). The cohort was divided into nirmatrelvir/ritonavir-treated and untreated groups. Between-group differences in baseline characteristics were adjusted using overlap weighting. Risks of postacute cardiovascular, neurological, respiratory, and autoimmune diagnoses and postacute symptoms (31-180 days) after SARS-CoV-2 infection were contrasted in treated/untreated groups using competing risks regressions (adjusted for demographics/vaccination status/comorbidities).</p><p><strong>Results: </strong>A total of 188 532 older Singaporeans were included; 5.8% (10 905/188 532) received nirmatrelvir/ritonavir. No significantly decreased risk of postacute sequelae (any sequelae: adjusted hazards ratio [aHR], 1.06; 0.94-1.19; cardiovascular sequelae: aHR, 1.01; 0.83-1.24; neurological sequelae: aHR, 1.09; 0.95-1.27; respiratory sequelae: aHR, 1.14; 0.84-1.55; autoimmune sequelae: aHR, 0.76; 0.53-1.09; or any postacute symptom: aHR, 0.97; 0.80-1.18) was observed up to 180 days post-infection in nirmatrelvir/ritonavir-treated individuals vs. untreated cases. Across all vaccination and age subgroups, no significantly decreased risk of any postacute diagnosis/symptom or any cardiovascular, neurological, respiratory, and autoimmune complications up to 180 days post-infection was observed.</p><p><strong>Discussion: </strong>Early outpatient receipt of nirmatrelvir/ritonavir did not significantly reduce risk of postacute cardiovascular, neurological, respiratory, and autoimmune sequelae or the risk of postacute symptoms in a boosted cohort of older Singaporeans.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"93-100"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dexamethasone in adults with viral meningitis: an observational cohort study.","authors":"Pelle Trier Petersen, Jacob Bodilsen, Micha Phill Grønholm Jepsen, Lykke Larsen, Merete Storgaard, Birgitte Rønde Hansen, Jannik Helweg-Larsen, Lothar Wiese, Hans Rudolf Lüttichau, Christian Østergaard Andersen, Henrik Nielsen, Christian Thomas Brandt","doi":"10.1016/j.cmi.2024.08.015","DOIUrl":"10.1016/j.cmi.2024.08.015","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate whether there is a dose-dependent association between empiric dexamethasone and outcome in viral meningitis.</p><p><strong>Methods: </strong>Observational cohort study of adults hospitalized for viral meningitis, both with and without a microbiologically confirmed diagnosis, in Denmark between 2015 and 2020. Dose-dependent associations between dexamethasone (one dose = 10 mg) and an unfavourable outcome (Glasgow Outcome Scale score 1-4) at 30 days after discharge were assessed using weighted logistic regression. Entropy balancing was used to compute weights.</p><p><strong>Results: </strong>Of 1025 included patients, 658 (64%) did not receive dexamethasone, 115 (11%) received 1-2 doses, 131 (13%) received 3-4 doses, and 121 (12%) received ≥5 doses. Among patients treated with dexamethasone, the median number of doses was higher for those without an identified pathogen than for those with a microbiologically confirmed viral aetiology (5 [interquartile range (IQR) 3-8] vs. 3 [IQR 2-5]; p < 0.001). Using no doses of dexamethasone as a reference, the weighted OR for an unfavourable outcome were 0.55 (95% CI, 0.29-1.07) for 1-2 doses, 1.13 (95% CI, 0.67-1.89) for 3-4 doses, and 1.43 (95% CI, 0.77-2.64) for ≥5 doses. In the subgroup of enteroviral meningitis, the weighted OR was 3.08 (95% CI, 1.36-6.94) for ≥5 doses, but decreased to 2.35 (95% CI, 0.65-8.40) when the reference group was restricted to patients treated with antibiotics for suspected bacterial meningitis.</p><p><strong>Discussion: </strong>This study showed no dose-dependent association between dexamethasone and an unfavourable outcome in patients with viral meningitis. In enteroviral meningitis, ≥5 doses were associated with an increased risk of an unfavourable outcome. However, sensitivity analysis indicated that the association was affected by unmeasured or residual confounding by severity.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":"87-92"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}